The lack of effect of ziprasidone on platelet serotonin concentration in schizophrenic patients
Ziprasidone is an atypical antipsychotic, with higher ratio of 5-HT2A/D2, 5-HT2C/D2 and 5-HT1A/D2 receptor binding than other antipsychotic drugs (Schmidt et al. 2001; Stahl and Shayegan 2007). It also blocks the serotonin transporter (5-HTT) and inhibits synaptic 5-HT reuptake (Tatsumi et al. 1999). Drugs that block the 5-HTT such as selective serotonin reuptake inhibitors (SSRI) have antidepressant properties, and ziprasidone is reported to have antidepressant effects in patients with depression (Moeller et al. 2007; Stahl and Shayegan 2007). At present, however, it is unknown whether ziprasidone affects the 5-HTT in vivo when given to patients in therapeutic doses. Platelet 5-HT concentration is a reliable marker of the 5-HTT blockade induced by SSRI, and reduced platelet 5-HT concentration is used as a marker of the biological activity of various SSRI (Muck-Seler et al. 2002). Therefore, the aim of the study was to investigate the effect of ziprasidone treatment on platelet 5-HT...
KeywordsSelective Serotonin Reuptake Inhibitor Ziprasidone Schizoaffective Disorder Selective Serotonin Reuptake Inhibitor Treatment Citrate Dextrose
Thanks are due to the psychiatric staff of the Clinical Hospital Centre Zagreb, Zagreb, Croatia. This work was supported by the Croatian Ministry of Science, Education and Sport (MSES), grants numbers 098-0982522-2455, 098-0922522-2457, 108-1083509-3513 and 108-1080037-0323. The comments in this work are solely the responsibility of the authors and do not necessarily represent the official views of the MSES. All protocols were approved by hospital review board and the Ethics Committee of the University Hospital Centre Zagreb and were therefore in line with the guidelines of the Declaration of Helsinki. There is no conflict of interest in relation to this article.
- Daniel DG, Zimbroff DL, Potkin SG, Reeves KR, Harrigan EP, Lakhsminarayanan M, the Ziprasidone Study Group (1999) Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Neuropsychopharmacology 20:491–505PubMedCrossRefGoogle Scholar
- Moeller O, Evers S, Deckert J, Baune BT, Dannlowski U, Nguyen DH, Arolt V, Hetzel G (2007) The impact of ziprasidone in combination with sertraline on visually-evoked event-related potentials in depressed patients with psychotic features. Prog Neuropsychopharmacol Biol Psychiatry 31:1440–1443PubMedCrossRefGoogle Scholar
- Stahl SM, Shayegan DK (2007) The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J Clin Psychiatr 64(Suppl 19):6–12Google Scholar